Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: Identification of potential therapeutic targets

Experimental Hematology

Volumn 37, Issue 8, 2009, Pages 879-886

  Giuliani, Nicola ^a   Mangoni, Marcellina ^a   Rizzoli, Vittorio ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; BETA CATENIN; BONE MORPHOGENETIC PROTEIN 2; BORTEZOMIB; DICKKOPF 1 PROTEIN; EPOXIMICIN; FRIZZLED PROTEIN; INTERLEUKIN 3; INTERLEUKIN 7; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; OSTEOCALCIN; PARATHYROID HORMONE[1-34]; PROTEASOME; PROTEASOME INHIBITOR; PS 1; RAC PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SCATTER FACTOR; STAT1 PROTEIN; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SOX9; UBIQUITIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4; WNT PROTEIN; WNT3A PROTEIN;

BONE REGENERATION; CELL DIFFERENTIATION; CELL INTERACTION; CLINICAL TRIAL; DRUG POTENCY; DRUG TARGETING; HUMAN; MESENCHYMAL STEM CELL; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OSTEOBLAST; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BONE DISEASES; CELL DIFFERENTIATION; CORE BINDING FACTOR ALPHA 1 SUBUNIT; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MESENCHYMAL STEM CELLS; MULTIPLE MYELOMA; OSTEOBLASTS; OSTEOGENESIS; WNT PROTEINS;

EID: 67650091219     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2009.04.004     Document Type: Review

References (88)

1. Kyle R.A., and Rajkumar S.V. Multiple myeloma. N Engl J Med 351 (2004) 1860-1873
2. Giuliani N., and Rizzoli V. GD Roodman. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 108 (2006) 3992-3996
3. Vejlgaard T., Abildgaard N., Jans H., et al. Abnormal bone turnover in monoclonal gammaopathy of undetermined significance: analyses of type I collagen telopeptide, osteocalcin, bone-specific alkaline phosphatase and propeptides of type I and type III. procollagens. Eur J Haematol 58 (1997) 104-108
4. Hjorth-Hansen H., Seifert M.F., Borset M., et al. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J Bone Miner Res 14 (1999) 256-263
5. Franceschi R.T., Ge C., Xiao G., et al. Transcriptional regulation of osteoblasts. Ann N Y Acad Sci 1116 (2007) 196-207
6. Deng Z.L., Sharff K.A., Tang N., et al. Regulation of osteogenic differentiation during skeletal development. Front Biosci 13 (2008) 2001-2021
7. Ducy P., Zhang R., Geoffroy V., et al. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89 (1997) 747-754
8. Franceschi R.T., and Xiao G. Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. J Cell Biochem 88 (2003) 446-454
9. Liu W., Toyosawa S., Furuichi T., et al. Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J Cell Biol 155 (2001) 157-166
10. Geoffroy V., Kneissel M., Fournier B., et al. High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage. Mol Cell Biol 22 (2002) 6222-6233
11. Shui C., Spelsberg T.C., Riggs B.L., and Khosla S. Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells. J Bone Miner Res 18 (2003) 213-221
12. Gronthos S., Zannettino A.C., Hay S.J., et al. Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci 116 (2003) 1827-1835
13. Xiao G., Jiang D., Thomas P., et al. MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor. Cbfa1. J Biol Chem 275 (2000) 4453-4459
14. Westendorf J.J., Kahler R.A., and Schroeder T.M. Wnt signaling in osteoblasts and bone diseases. Gene 341 (2004) 19-39
15. Krishnan V., Bryant H.U., and Macdougald O.A. Regulation of bone mass by Wnt signaling. J Clin Invest 116 (2006) 1202-1209
16. Gordon M.D., and Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 281 (2006) 22429-22433
17. Bennett C.N., Longo K.A., Wright W.S., et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A 102 (2005) 3324-3329
18. Rawadi G., Vayssiere B., Dunn F., et al. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 18 (2003) 1842-1853
19. Niida A., Hiroko T., Kasai M., et al. DKK1, a negative regulator of Wnt signaling, is a target of the beta-catenin/TCF pathway. Oncogene 23 (2004) 8520-8526
20. Galli L.M., Barnes T., Cheng T., et al. Differential inhibition of Wnt-3a by Sfrp-1, Sfrp-2, and Sfrp-3. Dev Dyn 235 (2006) 681-690
21. Li J., Sarosi I., Cattley R.C., et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39 (2006) 754-766
22. Kawano Y., and Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116 (2003) 2627-2634
23. Boyden L.M., Mao J., Belsky J., et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346 (2002) 1513-1521
24. Gong Y., Slee R.B., Fukai N., et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107 (2001) 513-523
25. Ai M., Holmen S.L., Van Hul W., et al. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol Cell Biol 25 (2005) 4946-4955
26. Kato M., Patel M.S., Levasseur R., et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 157 (2002) 303-314
27. Gaur T., Lengner C.J., Hovhannisyan H., et al. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem 280 (2005) 33132-33140
28. Bennett C.N., Longo K.A., Wright W.S., et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A 102 (2005) 3324-3329
29. de Boer J., Siddappa R., Gaspar C., et al. Wnt signaling inhibits osteogenic differentiation of human mesenchymal stem cells. Bone 34 (2004) 818-826
30. Boland G.M., Perkins G., Hall D.J., et al. Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J Cell Biochem 93 (2004) 1210-1230
31. Baksh D., Boland G.M., and Tuan R.S. Cross-talk between Wnt signaling pathways in human mesenchymal stem cells leads to functional antagonism during osteogenic differentiation. J Cell Biochem 101 (2007) 1109-1124
32. Baksh D., and Tuan R.S. Canonical and non-canonical wnts differentially affect the development potential of primary isolate of human bone marrow mesenchymal stem cells. J Cell Physiol 212 (2007) 817-826
33. Li X., Liu P., Liu W., et al. Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet 37 (2005) 945-952
34. van der Horst G., van der Werf S.M., Farih-Sips H., et al. Downregulation of Wnt signaling by increased expression of Dickkopf-1 and -2 is a prerequisite for late-stage osteoblast differentiation of KS483 cells. J Bone Miner Res 20 (2005) 1867-1877
35. Vaes B.L., Dechering K.J., van Someren E.P., et al. Microarray analysis reveals expression regulation of Wnt antagonists in differentiating osteoblasts. Bone 36 (2005) 803-811
36. Ling L., Nurcombe V., and Cool S.M. Wnt signaling controls the fate of mesenchymal stem cells. Gene 433 (2009) 1-7
37. Katoh M., and Katoh M. WNT signaling pathway and stem cell signaling network. Clin Cancer Res 13 (2007) 4042-4045
38. Chang J., Sonoyama W., Wang Z., et al. Noncanonical Wnt-4 signaling enhances bone regeneration of mesenchymal stem cells in craniofacial defects through activation of p38 MAPK. J Biol Chem 282 (2007) 30938-30948
39. Liu Y., Rubin B., Bodine P.V., et al. Wnt5a induces homodimerization and activation of Ror2 receptor tyrosine kinase. J Cell Biochem 105 (2008) 497-502
40. Liu Y., Ross J.F., Bodine P.V., et al. Homodimerization of Ror2 tyrosine kinase receptor induces 14-3-3(beta) phosphorylation and promotes osteoblast differentiation and bone formation. Mol Endocrinol 21 (2007) 3050-3061
41. Liu Y., Bhat R.A., Seestaller-Wehr L.M., et al. The orphan receptor tyrosine kinase Ror2 promotes osteoblast differentiation and enhances ex vivo bone formation. Mol Endocrinol 21 (2007) 376-387
42. Billiard J., Way D.S., Seestaller-Wehr L.M., et al. The orphan receptor tyrosine kinase Ror2 modulates canonical Wnt signaling in osteoblastic cells. Mol Endocrinol 19 (2005) 90-101
43. Takada I., Mihara M., Suzawa M., et al. A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation. Nat Cell Biol 9 (2007) 1273-1285
44. Giuliani N., Colla S., Morandi F., et al. myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 106 (2005) 2472-2483
45. Corre J., Mahtouk K., Attal M., et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 21 (2007) 1079-1088
46. Garderet L., Mazurier C., Chapel A., et al. Mesenchymal stem cell abnormalities in patients with multiple myeloma. Leuk Lymphoma 48 (2007) 2032-2041
47. Arnulf B., Lecourt S., Soulier J., et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 21 (2007) 158-163
48. Mori Y., Shimizu N., Dallas M., et al. Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 104 (2004) 2149-2154
49. Ely S.A., and Knowles D.M. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gamyelomaopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol 160 (2002) 1293-1299
50. Weitzmann M.N., Roggia C., Toraldo G., et al. Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J Clin Invest 110 (2002) 1643-1650
51. Giuliani N., Colla S., Sala R., et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 100 (2002) 4615-4621
52. Standal T., Abildgaard N., Fagerli U.M., et al. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 109 (2007) 3024-3030
53. Hong J.H., Hwang E.S., McManus M.T., et al. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 309 (2005) 1074-1078
54. Li B., Shi M., Li J., et al. Elevated tumor necrosis factor-alpha suppresses TAZ expression and impairs osteogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma. Stem Cells Dev 16 (2007) 921-930
55. Krishnan V., Moore T.L., Ma Y.L., et al. Parathyroid hormone bone anabolic action requires Cbfa1/Runx2-dependent signaling. Mol Endocrinol 17 (2003) 423-435
56. Jilka R.L. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40 (2007) 1434-1446
57. Zhao Z., Zhao M., Xiao G., et al. Gene transfer of the Runx2 transcription factor enhances osteogenic activity of bone marrow stromal cells in vitro and in vivo. Mol Ther 12 (2005) 247-253
58. Ehrlich L.A., Chung H.Y., Ghobrial I., et al. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood 106 (2005) 1407-1414
59. Lee J.W., Chung H.Y., Ehrlich L.A., et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 103 (2004) 2308-2315
60. Giuliani N., Morandi F., Tagliaferri S., et al. Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients. Blood 107 (2006) 841-842
61. Tian E., Zhan F., Walker R., et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349 (2003) 2483-2494
62. Giuliani N., Morandi F., Tagliaferri S., et al. Production of wnt inhibitors by myeloma cells: potential effects on canonical wnt pathway in the bone microenvironment. Cancer Res 67 (2007) 7665-7674
63. Oshima T., Abe M., Asano J., et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 106 (2005) 3160-3165
64. De Toni F., Racaud-Sultan C., Chicanne G., et al. A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia. Oncogene 25 (2006) 3113-3122
65. Gunn W.G., Conley A., Deininger L., et al. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 24 (2006) 986-991
66. Qiang Y.W., Chen Y., Stephens O., et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 112 (2008) 196-207
67. Yaccoby S., Ling W., Zhan F., et al. Antibody-based inhibition of DKK1 suppresses tumor- induced bone resorption and multiple myeloma growth in- vivo. Blood 109 (2007) 2106-2111
68. Qiang Y.W., Shaughnessy Jr. J.D., and Yaccoby S. Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood 112 (2008) 374-382
69. Edwards C.M., Edwards J.R., Lwin S.T., et al. Mundy GR. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 111 (2008) 2833-2842
70. Garrett I.R., Chen D., Gutierrez G., et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 111 (2003) 1771-1782
71. Zhao M., Qiao M., Oyajobi B.O., et al. E3 ubiquitin ligase Smurf1 mediates core-binding factor alpha1/Runx2 degradation and plays a specific role in osteoblast differentiation. J Biol Chem 278 (2003) 27939-27944
72. Zangari M., Esseltine D., Lee C.K., et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 131 (2005) 71-73
73. Zangari M., Yaccoby S., Cavallo F., et al. Response to bortezomib and activation of osteoblasts in multiple myeloma. Clin Lymphoma Myeloma 7 (2006) 109-114
74. Shimazaki C., Uchida R., Nakano S., et al. High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation. Leukemia 19 (2005) 1102-1103
75. Heider U., Kaiser M., Muller C., et al. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 77 (2006) 233-238
76. Terpos E., Heath D.J., Rahemtulla A., et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodeling in patients with relapsed multiple myeloma. Br J Haematol 135 (2006) 688-692
77. Giuliani N., Morandi F., Tagliaferri S., et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 110 (2007) 334-338
78. Mukherjee S., Raje N., Schoonmaker J.A., et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 118 (2008) 491-504
79. Qiang Y.W., Hu B., Chen Y., et al. Bortezomib induces osteoblast differentiation via Wnt-independent activation of {beta}-catenin/TCF signaling. Blood 113 (2009) 4319-4330
80. Girotra M., Rubin M.R., and Bilezikian J.P. The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord 7 (2006) 113-121
81. Bellido T., Ali A.A., Plotkin L.I., et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 278 (2003) 50259-50272
82. Kousteni S., and Bilezikian J.P. The cell biology of parathyroid hormone in osteoblasts. Curr Osteoporos Rep 6 (2008) 72-76
83. Weber J.M., Forsythe S.R., Christianson C.A., et al. Parathyroid hormone stimulates expression of the Notch ligand Jagged1 in osteoblastic cells. Bone 39 (2006) 485-493
84. Calvi L.M., Adams G.B., Weibrecht K.W., et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425 (2003) 841-846
85. Zhang J., Niu C., Ye L., et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425 (2003) 836-841
86. Garrett R.W., and Emerson S.G. The role of parathyroid hormone and insulin-like growth factors in hematopoietic niches: physiology and pharmacology. Mol Cell Endocrinol 288 (2008) 6-10
87. Pennisi A., Ling W., Perkins P., et al. PTH and bortezomib suppress growth of primary human myeloma through increased bone formation in vivo. [abstract]. Blood 108 (2006) Abstract 509
88. Zangari M., Pappas L., Zhan F., et al. Parathyroid hormones (PTH) serum variations are associated with bortezomib response in multiple myeloma patients. [abstract]. Blood 112 (2008) Abstract 2783